Compare Hims and Hers Health Inc (HIMS) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while Marsh & McLennan Companies, Inc. trades at $175.94 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 12.9× Hims and Hers Health Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| HIMS | MRSH | |
|---|---|---|
Market Cap | $6.55B | $84.31B |
Volume | 14,842,814 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $62.76 | $207.02 |
52-Week Low | $14.52 | $157.32 |
Typical Hold Time | 21 Days | 109 Days |
Enterprise Value | $7.25B | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
Marsh (MRSH) trades at $175.76, up 1.21% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust fundamentals, including a 25.72% ROE and 14.24% net income margin, alongside the recent acquisition of Accel Holdings announced on October 2, 2026. Revenue has grown steadily, reaching $27.0B in 2025, though profit margins have slightly softened.
The outlook remains positive with a consensus price target of $202.71, implying 15% upside, but risks include high valuation multiples and competitive pressures. Analysts are predominantly neutral, with 65% hold ratings, suggesting cautious optimism amid solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
